PSAR16117 / ARST1431 / Angela Girvin
Basic Study Information
Purpose:
This randomized phase III trial studies how well combination chemotherapy (vincristine
sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan
hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus
in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues,
such as muscle), and has an intermediate chance of coming back after treatment (intermediate
risk). Drugs used in chemotherapy work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Combination chemotherapy and temsirolimus may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet
known whether combination chemotherapy or combination chemotherapy plus temsirolimus
is more effective in treating patients with intermediate-risk rhabdomyosarcoma.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Angela Girvin
Study Contact Information
Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search